← All trials

NCT04594707

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jan 29, 2021
Primary completion
Dec 30, 2028
Completion date
Dec 30, 2028
First posted
Oct 20, 2020
Last posted
Dec 9, 2020
Enrollment
700
Arms / groups
1 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.